ArticleInternal medicine (Tokyo, Japan)2026
Four Metachronous Cancers: Mutation Profiling Can Be Used to Distinguish Multiple Primary Cancers from Metastases.
Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Distinguishing between primary and metastatic tumors is critical in patients with multiple cancers. We present the case of a man in his 70s with quadruple carcinoma, squamous cell carcinoma in both lungs, invasive urothelial carcinoma of the bladder, and esophageal cancer, discovered during follow-up after sigmoid colon cancer surgery. A histopathological analysis, including immunostaining, could not confirm whether these were primary or metastatic cancer. A comprehensive oncogene mutation analysis using next-generation sequencing revealed distinct gene mutations in each tumor, confirming that all were primary cancers of heterogeneous origin. Our findings highlight the importance of advanced genomic studies on complex cancer cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.